Dobrzycka Bozena, Terlikowski Sławomir J, Kowalczuk Oksana, Niklińska Wiesława, Chyczewski Lech, Kulikowski Marek
Department of Gynecological and Obstetrical Nursing, Medical University of Białystok, Poland.
Folia Histochem Cytobiol. 2009;47(2):221-4. doi: 10.2478/v10042-009-0039-6.
RAS genes are the most frequently mutated oncogenes detected in human cancer. In this study we analyzed the presence of mutations at codon 12 of the KRAS gene in 78 women with ovarian tumor, including 64 invasive ovarian cancers and 14 borderline ovarian tumors, using an RFLP-PCR technique and we evaluated whether such alterations were associated with the selected clinicopathological parameters of the patients. KRAS codon 12 gene mutations were found in 6,2% of ovarian cancer tissue and in 14,3% of the borderline ovarian tumor. KRAS mutations were found with a significantly higher frequency in mucinous and borderline tumors compared to serous tumors (p<0,01). Mutation frequency was correlated with the histological type of tumor, but not with stage, grade or patients age.
RAS基因是在人类癌症中检测到的最常见的突变癌基因。在本研究中,我们使用RFLP-PCR技术分析了78例卵巢肿瘤女性患者(包括64例浸润性卵巢癌和14例交界性卵巢肿瘤)中KRAS基因第12密码子的突变情况,并评估了这些改变是否与患者所选的临床病理参数相关。在6.2%的卵巢癌组织和14.3%的交界性卵巢肿瘤中发现了KRAS第12密码子基因突变。与浆液性肿瘤相比,在黏液性和交界性肿瘤中发现KRAS突变的频率显著更高(p<0.01)。突变频率与肿瘤的组织学类型相关,但与分期、分级或患者年龄无关。